BlackJack3D
SPDR S&P Biotech ETF (NYSEARCA:XBI) is a popular and very liquid way to invest in the biotech sector. The inception of this ETF was on January 31, 2006; it has about $6.4 billion in assets under management, and it has a gross
XBI: 3 Reasons To Buy The Pullback And Hold This Biotech ETF Forever
Summary
- SPDR S&P Biotech ETF offers a buying opportunity after a recent decline and trades close to the 200-day moving average.
- XBI has a strong long-term track record, providing generous total returns for shareholders.
- The biotech sector is seeing increased levels of merger and acquisition deals, indicating potential undervaluation in biotech stocks.
Long-time stock market investor focused on strategic buying opportunities with dividend and value stocks. This investment strategy has resulted in a near 5 star rating on Tipranks.com and over 9,000 followers on Seeking Alpha. Follow me on Twitter for my latest trading ideas: @Hawkinvest1
Analyst’s Disclosure:I/we have a beneficial long position in the shares of XBI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.